BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34364049)

  • 1. Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Hu J; Gao M; Zhang Y; Wang Y; Qiao Z; Zhang W; Wang Q; Yan L; Qian H
    Bioorg Chem; 2021 Oct; 115():105229. PubMed ID: 34364049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
    Nie C; Li Q; Qiao Y; Hu J; Gao M; Wang Y; Qiao Z; Wang Q; Yan L; Qian H
    Eur J Med Chem; 2020 May; 194():112236. PubMed ID: 32217416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
    Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of first-in-class highly selective TRPV1 antagonists with dual analgesic and hypoglycemic effects.
    Liu C; Wang W; Zhao S; Chen S; Chen H; Wang S; Li Z; Qian H; Tian X
    Bioorg Med Chem; 2024 Jun; 107():117750. PubMed ID: 38776567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
    Voight EA; Gomtsyan AR; Daanen JF; Perner RJ; Schmidt RG; Bayburt EK; DiDomenico S; McDonald HA; Puttfarcken PS; Chen J; Neelands TR; Bianchi BR; Han P; Reilly RM; Franklin PH; Segreti JA; Nelson RA; Su Z; King AJ; Polakowski JS; Baker SJ; Gauvin DM; Lewis LR; Mikusa JP; Joshi SK; Faltynek CR; Kym PR; Kort ME
    J Med Chem; 2014 Sep; 57(17):7412-24. PubMed ID: 25100568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
    Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
    J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
    Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation as Transient Receptor Potential Vanilloid 1 Antagonists.
    Yan L; Wang J; Pan M; Qiu Q; Huang W; Qian H
    Chem Biol Drug Des; 2016 Feb; 87(2):306-11. PubMed ID: 26360809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
    García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
    J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of N
    Gao M; Nie C; Li J; Song B; Cheng X; Sun E; Yan L; Qian H
    Bioorg Chem; 2019 Feb; 82():100-108. PubMed ID: 30278281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of carbamide derivatives bearing tetrahydroisoquinoline moieties and biological evaluation as analgesia drugs in mice.
    Qiu Q; Wang J; Deng X; Qian H; Lin H; Huang W
    Arch Pharm (Weinheim); 2015 May; 348(5):347-52. PubMed ID: 25824579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
    Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
    J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
    Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region.
    Kim MS; Ryu H; Kang DW; Cho SH; Seo S; Park YS; Kim MY; Kwak EJ; Kim YS; Bhondwe RS; Kim HS; Park SG; Son K; Choi S; DeAndrea-Lazarus IA; Pearce LV; Blumberg PM; Frank R; Bahrenberg G; Stockhausen H; Kögel BY; Schiene K; Christoph T; Lee J
    J Med Chem; 2012 Oct; 55(19):8392-408. PubMed ID: 22957803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
    J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists.
    Sun W; Kim HS; Lee S; Jung A; Kim SE; Ann J; Yoon S; Choi S; Lee JH; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Schiene K; Stockhausen H; Christoph T; Frormann S; Lee J
    Bioorg Med Chem Lett; 2015 Feb; 25(4):803-6. PubMed ID: 25597011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Brown BS; Keddy R; Zheng GZ; Schmidt RG; Koenig JR; McDonald HA; Bianchi BR; Honore P; Jarvis MF; Surowy CS; Polakowski JS; Marsh KC; Faltynek CR; Lee CH
    Bioorg Med Chem; 2008 Sep; 16(18):8516-25. PubMed ID: 18722778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.